Alder BioPharmaceuticals (ALDR) Given a $22.00 Price Target at Canaccord Genuity

Marco Green
January 14, 2018

Senzar Asset Management Llc who had been investing in Alder Biopharmaceuticals Inc for a number of months, seems to be bullish on the $1.18B market cap company. The volume of the company in the last trading session was 1.4 Million. The company's outstanding shares are 15.94 Million. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since January 13, 2017 and is downtrending. It has outperformed by 10.16% the S&P500. Alder BioPharmaceuticals has a 12 month low of $8.60 and a 12 month high of $25.45. The institutional investor held 121,700 shares of the restaurants company at the end of 2017Q3, valued at $6.54M, up from 103,000 at the end of the previous reported quarter. Following the completion of the sale, the insider now owns 116,451 shares in the company, valued at approximately $1,257,670.80. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company's stock valued at $255,000 after acquiring an additional 1,734 shares during the period.

The stock decreased 0.56% or $0.1 during the last trading session, reaching $17.8. About 13,388 shares traded.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded up $0.55 on Friday, reaching $17.90. It has underperformed by 50.37% the S&P500. Teachers Advisors LLC now owns 84,705 shares of the biopharmaceutical company's stock valued at $970,000 after acquiring an additional 3,091 shares during the period. Redmile Group LLC grew its position in shares of Alder BioPharmaceuticals by 16.4% during the second quarter.

BidaskClub cut shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a sell rating to a strong sell rating in a research report report published on Tuesday, December 19th. Therefore 88% are positive. Zacks Investment Research lowered Alder BioPharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, October 13th. (NASDAQ:ALDR) earned "Buy" rating by Aegis Capital on Thursday, June 29. (NASDAQ:ALDR) to report earnings on February, 22. The firm has "Buy" rating by Needham given on Wednesday, November 8. On Tuesday, March 29 the stock rating was maintained by Credit Suisse with "Outperform".

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. The rating was maintained by BMO Capital Markets on Tuesday, January 2 with "Buy".

Rhumbline Advisers boosted its stake in Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) earned "Outperform" rating by Wells Fargo on Thursday, April 21.

Since September 7, 2017, it had 0 buys, and 2 selling transactions for $4.70 million activity. See Alder Biopharmaceuticals, Inc. They expect $-1.08 earnings per share, down 11.34% or $0.11 from last year's $-0.97 per share. TEVA's profit will be $762.00M for 7.36 P/E if the $0.75 EPS becomes a reality. In the most recent quarterly financial report, for the quarter ending Sep. Its up 0.01, from 1.23 in 2017Q2. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 100 funds opened positions while 428 raised stakes. (NASDAQ:FEYE). Grassi Inv Mgmt stated it has 0.03% of its portfolio in FireEye, Inc. 446,000 are held by Bedrijfstakpensioenfonds Voor De Media Pno.

Several institutional investors have recently modified their holdings of ALDR.

U.S. Global Investors, Inc. At present, 1 analysts call it Sell, while 1 think it is Hold. Beach Invest Counsel Pa has 250,261 shares. Arrow Fincl Corporation owns 34,323 shares for 0.44% of their portfolio. Vantage Inv Lc stated it has 13,870 shares or 0.27% of all its holdings. Hightower Advisors Limited Liability Company holds 178,931 shares. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. The firm has "Buy" rating by Standpoint Research given on Monday, July 27. The company was downgraded on Monday, October 5 by Piper Jaffray. The stock has a market cap of 68.22 Million. They set an outperform rating and a $20.00 target price for the company. The company was maintained on Monday, January 8 by BMO Capital Markets. The firm has "Hold" rating by Credit Suisse given on Thursday, August 24.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article